VA-DXC-TECHNOLOGY
15.9.2021 10:02:09 CEST | Business Wire | Press release
DXC Technology (NYSE: DXC) and Lenovo today announced a collaboration with visionary robotics scientist Dr. Peter Scott-Morgan and his philanthropic foundation to develop ambitious assistive technology solutions by integrating the latest hardware, software, and artificial intelligence (AI) technologies to empower people with disabilities, illnesses, and other challenging conditions.
Scott-Morgan, known as the “world’s first human cyborg", is pushing technology to extend and enrich lives. He was diagnosed with motor neuron disease (MND) – also known as amyotrophic lateral sclerosis (ALS) – in 2017. When the first symptoms emerged, Scott-Morgan began exploring ways to upend the typical disease progression through his belief in the limitless potential of technology. Scott-Morgan’s vision is to: “Make the vulnerable safe, the powerless strong, the unfulfilled thrive.”
“The bedrock of our collaboration is a belief in the untapped potential of technology to unleash your dreams - whatever you are, whatever your background, whatever your circumstances, whatever your ambitions,” Scott-Morgan said. Initially told by doctors he had only two years to live, Scott-Morgan has a mantra: “Add hope with AI and Robotics!”
DXC and Lenovo – alongside a team of volunteers and leading technologists – will provide hardware, software support, integration, and artificial intelligence expertise. Key initiatives include:
- Developing autonomous, self-driving wheelchairs to navigate homes and beyond;
- Preserving personality with an avatar that renders quickly in photo-realistic detail;
- Leveraging augmented reality (AR) as a user interface controlled with only eye movements;
- Accelerating the generation and customization of emotionally expressive digital voices; and
- Embedding smart technology throughout a family home to enhance the life of all its occupants.
In addition to developing custom solutions, Lenovo has donated computing equipment for Scott-Morgan’s home-office. Calvin Crosslin, Lenovo’s Chief Diversity Officer and President of the Lenovo Foundation said: “We have a responsibility to make powerful technology as accessible as possible and create new opportunities. This is precisely why we rally behind the idea of smarter technology for all, and I am grateful to Dr. Scott-Morgan for inviting us to collaborate and share some small part of his extraordinary vision.”
DXC will act as technology integrator. Deploying capabilities from the Enterprise Technology Stack, DXC will bring technology know-how and experience to ensure seamless and secure integration across infrastructure, applications, analytics, and engineering solutions.
“Peter is an astonishing inspiration,” said Steve Turpie, President, EMEA at DXC. “The DXC team will offer consulting and support to define requirements, the target architecture, and the technology roadmap. Specifically, they will enable the functions for eye tracking, virtual keyboards, speech, and avatar performance. Peter, with the Foundation, has a tireless passion to challenge our thinking on how technology can be used to enhance people’s lives and society.”
Learn more about Dr. Peter Scott-Morgan, including his background, ongoing research, and opportunities to get involved through The Scott-Morgan Foundation .
“I applied a lifetime of research to rewrite my own future - an extraordinarily lucky break! But far more important, we’ve now the chance to rewrite the future for millions - eventually billions - by applying the lessons learned to make the vulnerable safe, the powerless strong, the unfulfilled thrive. I wanted a way to break free of my suddenly inadequate body, to overcome a devastating diagnosis and reimagine what ‘terminal disease’ could mean. But we can help everyone who feels disadvantaged. They can rise like a phoenix! With extraordinary support from my husband Francis, countless kind and brilliant collaborators, and technology leaders like DXC and Lenovo, I find the once-dark future incredibly bright.”
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services across the Enterprise Technology Stack to drive new levels of performance, competitiveness, and customer experience. Learn more about how we deliver excellence for our customers and colleagues at DXC.com .
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services, and software) millions of customers every day and together create a more inclusive, trustworthy, and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub .
About Lenovo Tech World 2021 and Dr Peter Scott-Morgan
Scott-Morgan joined Lenovo at its Tech World 2021 event on September 8 to speak with Thorsten Stremlau, Lenovo’s director of strategic enterprise consulting, about their shared goals of delivering smarter technology for all.
“I am deeply humbled to work with Peter, an absolutely brilliant scientist and inspiring human,” said Stremlau, who is leading Lenovo’s efforts. “We focus a lot on increasing accessibility and diversity at Lenovo , and this is a singular opportunity to ensure our innovation makes a real difference – for both Peter and, I hope, many others.”
About other partners supporting The Scott-Morgan Foundation
Other key collaborators already working with Scott-Morgan on this initiative include Matthew Aylett of CereProc, Amanda Darby of Optimize3D at Pinewood Studios, and Ari Shapiro of Embody Digital.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005415/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom